Shyaam, Nice research - that's tens of $Billion of addressable...

Shyaam,

Nice research - that's tens of $Billion of addressable market potential.

We are now seeing a transformation happening in the ANP value proposition.

Most of us - and the instos - are here because of the near term DMD opportunity.

i.e. One 12 month trial away from commercial approval in a $7B unmet market.

However, the new targets for immunotherapy in Cancer indications will take ANP to the next level.

As you say "... there are no patented drugs or references to any researched compounds that modulate LTBP4"

The value drivers here are incredible - now we get to appreciate the exhaustive IP protection work carried out by George.

Partnerships is the key word for non DMD indications....unless of course a cashed up Pharma wants to take the lot early

.